Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Two years' experience of implementing a comprehensive telemedical stroke network comprising in mainly rural region: the Transregional Network for Stroke Intervention with Telemedicine (TRANSIT-Stroke).
Gabriel KMA, Jírů-Hillmann S, Kraft P, Selig U, Rücker V, Mühler J, Dötter K, Keidel M, Soda H, Rascher A, Schneider R, Pfau M, Hoffmann R, Stenzel J, Benghebrid M, Goebel T, Doerck S, Kramer D, Haeusler KG, Volkmann J, Heuschmann PU, Fluri F. Gabriel KMA, et al. Among authors: doerck s. BMC Neurol. 2020 Mar 19;20(1):104. doi: 10.1186/s12883-020-01676-6. BMC Neurol. 2020. PMID: 32192438 Free PMC article.
Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.
Huhn K, Bayas A, Doerck S, Frank B, Gerbershagen K, Hellwig K, Kallmann B, Kleinschnitz C, Kleiter I, Lee DH, Limmroth V, Mäurer M, Meuth S, Rieckmann P, Ruck T, Gold R, Linker RA. Huhn K, et al. Among authors: doerck s. J Neurol. 2018 Jul;265(7):1521-1527. doi: 10.1007/s00415-018-8871-2. Epub 2018 Apr 25. J Neurol. 2018. PMID: 29696498
Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation.
Pfeuffer S, Schmidt R, Straeten FA, Pul R, Kleinschnitz C, Wieshuber M, Lee DH, Linker RA, Doerck S, Straeten V, Windhagen S, Pawlitzki M, Aufenberg C, Lang M, Eienbroeker C, Tackenberg B, Limmroth V, Wildemann B, Haas J, Klotz L, Wiendl H, Ruck T, Meuth SG. Pfeuffer S, et al. Among authors: doerck s. J Neurol. 2019 Jan;266(1):165-173. doi: 10.1007/s00415-018-9117-z. Epub 2018 Nov 16. J Neurol. 2019. PMID: 30446966
Effects of natalizumab treatment on Foxp3+ T regulatory cells.
Stenner MP, Waschbisch A, Buck D, Doerck S, Einsele H, Toyka KV, Wiendl H. Stenner MP, et al. Among authors: doerck s. PLoS One. 2008 Oct 6;3(10):e3319. doi: 10.1371/journal.pone.0003319. PLoS One. 2008. PMID: 18836525 Free PMC article.